Financial updates
Pharming Group reports interim financial results for the first quarter of 2019
Pharming Group N.V. presents its (unaudited) interim financial report for the first quarter ended 31 March 2019.
Main results compared to Q1 2018:
- 19.5% increase in revenues
- 49% increase in operating profit
- 23% increase in net profit.
''We are pleased to report strong results today in a period of intense competition. Pharming’s revenue and profit performance confirm the success of our in-market strategy for RUCONEST® as we see continued growth in underlying demand for the product.''
- Sijmen de Vries - CEO